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Abstract
Disturbance of apoptosis is an established factor in tumorigenesis. The role of apoptosis in tumor progression is not yet
clear. In the present study we compared the tendency to spontaneous apoptosis (and the proliferative capacity) of tumor cells
derived from primary (PT) and metastatic tumor (MT) cells of several AKR lymphoma variants. Apoptosis-related gene
expression was also compared. Our results indicate that release from apoptosis has a role in the tumor progression of this T
cell lymphoma. At the cellular level, a markedly lower apoptotic tendency was observed in MT than in PT cells. The existence
of macrophages only in PT also supports the presence of apoptotic cells in local but not in MTs. By contrast, proliferative
capacity does not determine tumor aggressiveness in this system. At the molecular level, we found a higher staining intensity
for bcl-2 in MT than in PT cells, suggesting that bcl-2 might be responsible for the reduced apoptosis in MT compared to PT
cells. Evidence for p53 overexpression was found in the MT cells of one of the variants but in none of the PT. Comparison of
Fas receptor, unexpectedly showed an increased expression in MT versus PT cells, possibly indicating resistance to Fas-
induced apoptosis in the MT cells. ß 2000 Elsevier Science B.V. All rights reserved.
Keywords: Apoptosis resistance; Tumor progression; Primary versus metastatic tumor; Apoptosis-related gene expression;
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1. Introduction
Cell proliferative capacity served for decades as a
criterion for evaluating cancer prognosis. It also con-
stitutes the basis for attack by chemo- and radiother-
apy. Disturbance in tumor cell deletion due to apop-
tosis has emerged during recent years as a factor in
tumorigenesis [1] and possibly in tumor progression
[2] and response to therapy [3].
The regulation of apoptosis is fundamental to
hematopoietic homeostasis. Therefore the acquisition
of lesions having an anti-apoptotic e¡ect may con-
stitute an important event in the genesis and possibly
evolution of hematological malignancies.
The role of release from apoptosis in tumor pro-
gression is not clear. Relatively few data exist at the
cellular level and data concerning determination of
apoptosis-related genes at various stages of tumor
progression are con£icting.
The p53 gene induces apoptotic cell death in cells
which have undergone damage to DNA. p53 modi-
¢cation is the most common genetic alteration in
human cancer [4]. The role of p53 in tumorigenesis
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is evident from the tendency of patients with the Li^
Fraumeni syndrome to develop at early ages various
types of neoplasia [5]. p53 de¢cient mice were found
to develop mainly lymphomas and sarcomas [6]. p53
has, however, been reported to play a role also in
tumor progression [7], whether at early or at late
[8] stages. Blyth et al. have shown a synergy between
c-myc transgene and p53 null genotype in the meta-
static potential of thymic lymphomas.
The survival promoting gene, bcl-2, is known to
play a role in lymphomagenesis in both humans [9]
and mice [10]. As for its role in tumor progression,
evidence for and against an enhanced malignant be-
havior of tumors overexpressing bcl-2, has been pre-
sented [11^14].
T cell lymphomas are among the most aggressive
lymphoproliferative diseases, and very resistant to
therapy. The AKR lymphoma is considered to be
a good model for human T cell non Hodgkin’s lym-
phomas. Interestingly, virus-associated T cell leuke-
mias/lymphomas are characterized by a poor prog-
nosis and rapid emergence of drug resistance [15].
We have been working in our laboratory on
tumor progression models of this malignancy. One
model consisted in isolating and characterizing
variants di¡ering in degree of malignancy [16^20].
Another model consisted in comparing cells derived
from primary tumors (PT) and metastatic tumors
(MT) of the same animal which displayed a di¡er-
ential biological behavior [21]. We have described
di¡erences in immunophenotype [22] and in sensitiv-
ity to cytotoxic drugs [17,23], lectins [24] and im-
mune reactions [25], between di¡erent malignancy
variants.
In the present study we have undertaken to ¢nd
out whether during tumor progression of AKR lym-
phoma a reduced tendency to programmed cell
death (PCD) is observed. We have indeed recent-
ly shown in one lymphoma variant, the TAU-47,
that MT cells had a much lower content in apo-
ptotic cells than PT cells [26]. In the present study,
we ¢rst extended the previous one by comparing
both the tendency to spontaneous PCD and prolifer-
ative activity between PT and MT cells of several
AKR lymphoma variants. We further attempted to
determine the role of apoptosis-related gene expres-
sion in the tumor progression-related reduced apo-
ptosis.
2. Materials and methods
2.1. Animals and tumors
AKR/J mice, 6^8 weeks old, were obtained from
the Tel-Aviv University Animal Breeding Center.
The tumor progression model used in the present
study consisted in comparing PT and MT cells de-
rived from the same animal in four AKR lymphoma
variants. The PTs consisted of the local tumors
formed at the s.c. site of inoculation while for MT
growths we used the tumorally enlarged mesenteric
lymph nodes which consisted of huge, up to 2000 mg
growths. The variants used in this study were: TAU-
45, TAU-47, TAU-44 and TAU-33 in order of in-
creasing malignancy.
Tumor cell suspensions were prepared as previ-
ously described [17]. For biological behavior experi-
ments, equal inocula of PT or MT cells were injected
s.c. in the back of mice (2U105 cells/0.2 ml RPMI
medium). Tumor development was evaluated by fol-
lowing PT and MT growth, as well as mice mortal-
ity. Each experimental group consisted of at least ¢ve
mice and experiments were repeated at least four
times.
2.2. DNA £ow cytometry
Cells derived from PT and MT of each of the
AKR lymphoma variants were incubated with propi-
dium iodide (50 Wg/ml) following the procedure of
Vindelov [27]. The data were analyzed on Cell Quest
Software BP, MultiCycle Phoenix Flow Systems,
Phoenix, AZ, USA.
2.3. Giemsa staining
Tumor cell suspensions were washed with PBS and
the pellet was spread on slides. Cells were ¢xed with
methanol and then stained with May^Grunwald^
Giemsa. The percentage of mitotic ¢gures, apoptotic
bodies as well as macrophages were counted at high
power ¢elds. A total of 300 cells was counted.
2.4. DNA fragmentation analysis by agarose gel
electrophoresis
DNA from PT and MT tumors of the AKR lym-
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phoma variants were analyzed by horizontal electro-
phoresis during 4 h on 1.5% agarose gel and visual-
ized by UV £uorescence after staining with ethidium
bromide (0.5 Wg/ml).
2.5. Analysis of Bcl-2 protein expression by £ow
cytometry
Single cell suspensions were washed with PBS and
red blood cells were removed by RBC bu¡er. Cells
were suspended at a concentration of 2U107 cells/ml
in SB (1% BSA (Sigma) in PBS, pH = 7.4) and sap-
onin 0.03% (Sigma), in order to permeabilize cells
[28]. The cells were incubated with hamster anti-
mouse-Bcl-2 mAb (PharMingen, USA, clone 3F11)
for 30 min at 4‡C. After washing with SB+saponin,
cells were incubated with FITC-conjugated goat anti-
Armenian hamster IgG (PharMingen, Jackson Im-
munoResearch Laboratories) for 30 min at 4‡C.
After two additional washes samples were analyzed
on a FACSort Becton Dickinson, (San Jose, CA,
USA) with WINMDI Joseph Trotter Scripps data
processing. Each experiment contained its own con-
trols, consisting of cells treated with secondary anti-
body only.
2.6. Analysis of p53 expression by £ow cytometry
Cells prepared as above were washed in PBS and
resuspended in bu¡er containing BSA 0.2%, Sodium
azide 0.002% and Triton X-100 0.05% to a concen-
tration of 3U107 cells/ml. The cells were incubated
with the PAb 240 or PAb 122, mouse anti-mouse p53
mAb (Chemocon, clone 240 and NeoMarker, clone
122, respectively) for 30 min. at room temperature.
After washing with the bu¡er, the cells were incu-
bated with PE-conjugated donkey anti-mouse IgG
(PharMingen, Jackson ImmunoResearch Laborato-
ries) for 30 min at room temperature. After washing
twice with the bu¡er, cells were analyzed by FACS as
above.
As p53 positive cells, we used the p53His175 mu-
tant - transfected H1299 p53 null human lung cancer
cells [29,30] - and the SkBr3 human breast carcinoma
cells (mutant 175 codon), kindly provided by Prof.
Moshe Oren and Dr. Giovanni Blandino from the
Department of Molecular Cell Biology, the Weizman
Institute of Science, Rehovot, Israel.
Cells from the H175 cell line were cultured in
RPMI containing 10% fetal calf serum (FCS),
4 mM glutamine-penicillin-streptomycin solution,
1:100 non essential amino acids and 1 mM Sodium
pyruvate. Cells from the SkBr3 line were cultured in
DMEM medium containing the above mentioned
supplements.
The PAb 240 antibody used by us recognizes the
epitope between residues 156^214 of both human
and mouse p53, including therefore the amino acid
Fig. 1. Comparison of metastatic dissemination according to or-
gan weight of mice inoculated with PT and MT cells of the
TAU-45 variant.
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at the 175 site (in which arginine was substituted by
histidine) [31]. The PAb 122 antibody recognizes a
conserved determinant between the 370^378 amino
acids at the C terminal end of the p53 protein.
2.7. Analysis of Fas expression by £ow cytometry
Cells prepared as above were washed in cold bu¡er
(1% FCS in PBS) and were suspended to a concen-
tration of 2U107 cells/ml. In order to reduce FcQii/iii
R-mediated antibody binding, the cells were incu-
bated with 0.25 Wg Fc Block (PharMingen, clone
2.4G2) per 1000 000 cells for 3 min, at 4‡C. After
washing, the cells were incubated with hamster
anti-mouse Fas mAb (PharMingen, clone Jo2) for
30 min at 4‡C in the dark. After washing with cold
bu¡er, cells were incubated with the same secondary
antibody as above and analyzed by FACS.
2.8. Statistical evaluation
Statistical evaluation was performed using Stu-
dent’s t-test.
3. Results
3.1. Comparison of the biological behavior of PT and
MT cells
A comparison of the in vivo biological behavior of
PT versus MT cells of the TAU-45 AKR lymphoma
variant is presented in Fig. 1. Twenty days after in-
oculating PT and MT cells subcutaneously, the
weight of spleen, thymus and lungs was compared
between the two groups of mice. The average weight
of all three organs (as well as that of kidney and
mesenteric lymph nodes, not shown) was higher in
mice inoculated with the MT cells than in those in-
jected with the PT cells. The di¡erence was statisti-
cally signi¢cant with regard to thymus (P6 0.0125)
and lungs (P6 0.01) but not for the spleen. A higher
mortality rate of the MT-bearing as compared to the
PT-inoculated mice was observed (not shown). The
same trend was seen when comparing the PT and
MT cells of the other two variants, TAU-44 and
TAU-33.
Fig. 2. Comparison of DNA £ow cytometry of PT and MT cells in three AKR lymphoma malignancy variants.
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Fig. 4. Comparison of apoptotic cell content between PT and MT cells in di¡erent AKR lymphoma variants - FACS analysis. (a)
DNA content; (b) forward scatter and (c) double plot of DNA content versus cell size. The data indicate the percentage of cells with
DNA content below that of G0/G1. They represent the average of 6^8 experiments. N.Sp. = Normal Spleen.
Fig. 3. Comparison of content in S and G2M phase cells according to DNA £ow cytometry between PT and MT cells of di¡erent
AKR lymphoma variants. N.Sp. = Normal Spleen. The data represent the average of 5^7 experiments for each of the variants.
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3.2. Comparison of DNA £ow cytometry pattern in
PT and MT AKR lymphoma cells
A comparison of DNA £ow cytometry in PT and
MT cells of the three AKR lymphoma variants in a
representative experiment is presented in Fig. 2. Very
marked di¡erences were observed between PT and
MT cells in all three variants, both with regard to
cell cycle phase distribution and to content in low
DNA containing (apoptotic) cells.
Fig. 3 presents the average of several experiments
of the cell cycle phase distribution according to
FACS analysis. The PT cells of all variants had a
much higher fraction of cells in the S and G2M
phases (constituting around 40% of the cells) than
the MT cells in which they represented only 4^8%.
The di¡erence between PT and MT cells was very
marked (U8.4, U4.7 and U8.7 in the PT versus
the MT cells for the TAU-45, TAU-44 and TAU-
33 variants, respectively) and highly signi¢cant for
Fig. 5. Dividing cells, apoptotic bodies and macrophages in the
PT cells of TAU-44. Tumor cells were ¢xed with methanol and
stained with May^Grunwald^Giemsa. Upper part: dividing
cells ; middle part: some apoptotic bodies (arrows) are seen;
lower part: a macrophage (arrow) is seen among tumor cells.
Fig. 6. Comparison of DNA fragmentation in PT and MT cells
of the AKR lymphoma. 1 = TAU-33-MT; 2 = TAU-33-PT;
3 = TAU-44-MT; 4 = TAU-44-PT; 5 = TAU-45-MT; 6 = TAU-
45-PT; 7 = normal spleen; 8 = marker (pUC18 DNA marker
HaeIII digest, 102^587 bp).
Table 1
Comparison of apoptotic cell content between PT and MT cells of di¡erent AKR lymphoma variants: FACS analysis according to
DNA content and forward scatter




(PT compared to MT)
AI PT/MT Apoptotic cells
(%) þ S.D.
P
(PT compared to MT)
AI PT/MT
N.Sp. 3.9 þ 2.4 5.3+ þ 0.9
TAU-45-PT 32.3 þ 11.4 P6 0.01 4.3 34.4 þ 11.2 P6 0.01 2.9
TAU-45-MT 7.5 þ 5.2 12.0 þ 1.8
TAU-44-PT 37.7 þ 12.3 P6 0.0005 15.6 21.6 þ 0.05 P6 0.0005 3.6
TAU-44-MT 2.4 þ 1.6 5.9 þ 3.3
TAU-33-PT 28.3 þ 8.3 P6 0.0005 9.0 19.6 þ 4.2 P6 0.0005 3.8
TAU-33-MT 3.1 þ 2.5 5.2 þ 5.3
These data represent the average of 6^8 experiments.
AI = Apoptotic index, N.Sp. = Normal spleen.
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the three variants (P6 0.0005). The proportion of
cells in the S phase was much higher than that in
the G2M phase in all cell types except for the
TAU-44-MT cells.
All the tumor cells except the TAU-45-MT cells
(which were close to diploid) were found to be
slightly hyperploid (not shown).
A comparison of content in apoptotic cells be-
tween PT and MT cells, calculated from the DNA
£ow cytometry data is shown in Fig. 4a and Table 1.
Cells and DNA containing particles with low DNA
content (sub G1) were in much higher quantities
in PT than in MT cells. The di¡erence between PT
and MT cells was highly signi¢cant in the three var-
iants, and was particularly marked in the TAU-44
variant.
A similar trend, although with less marked di¡er-
ences between PT and MT cells, was seen while sum-
marizing the data of forward scatter (Fig. 4b and
Table 1). The percentage of small cells (between
FACS channels 0^60) was much higher in the PT
than in the MT cell population.
A double plot presentation of DNA content versus
cell size (according to forward scatter) is presented in
Fig. 4c. Again, the fraction of apoptotic cells, repre-
sented here by the subpopulation of small low DNA
containing cells, is much higher in the PT than in the
MT cells, in the three AKR lymphoma variants.
3.3. Comparison of mitotic activity, apoptosis and
macrophage content in PT and MT populations
according to cell morphology
Staining of tumor cells by May^Grunwald^Giemsa
(Fig. 5 and Table 2) showed a higher content in
apoptotic bodies in the PT cells than in the MT
ones. Mitotic ¢gures were observed only among the
PT cells. Macrophages were also seen only in the PT,
¢tting the presence of the high amount of apoptotic
bodies in these growths and their paucity in the MTs.
Fig. 7. Comparison of Bcl-2 expression in PT and MT cells of AKR lymphoma.
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3.4. Comparison of DNA fragmentation between PT
and MT cells
DNA fragmentation, as seen in agarose gel elec-
trophoresis, was compared between PT and MT cells
of the TAU-45, TAU-44 and TAU-33 AKR lympho-
ma variants (Fig. 6). A ladder type pattern of DNA
fragmentation was observed in the PT cells of all
three variants (lanes 2, 4 and 6). As for the MT cells,
some DNA fragmentation, typical for apoptotic
cells, was seen only in the TAU-45 (lane 5) but
none was observed in those of the TAU-33 and
TAU-44 cells (lanes 1 and 3, respectively). No
DNA fragmentation was seen in the normal spleno-
cytes (lane 7).
3.5. Expression of apoptosis-related genes in PT
versus MT cells
Fig. 7 presents a comparison of Bcl-2 expression as
examined by FACS analysis of cells derived from PT
and MT cells. As seen in this representative experi-
ment, the expression of Bcl-2, as shown by intensity
peaks, was markedly higher in the MT than in the
PT cells in all three variants. The quantitative anal-
ysis of all the experiments done with regard to the
bcl-2 staining intensity in the PT and MT cells is
presented in Fig. 8a. Almost four fold higher £uo-
rescence values of the bcl-2 protein content were ob-
Fig. 8. Comparison of Bcl-2 protein expression between PT and
MT according to £uorescence intensity peaks (a) and Bcl2 cell
percentage (b). Bcl-2 expression = the average of the di¡erences
between the £uorescence intensity observed with both primary
and secondary antibody minus that observed with secondary
antibody only. The data represent the average of ¢ve experi-
ments.
Fig. 9. Comparison of p53 expression, as detected by the PAb
240 and PAb122 antibodies, between the TAU-47-PT and the
TAU-47-MT cells. The p53 His175 mutant (transfected H1299
p53 null human lung cancer cells) served as a control in this ex-
periment.
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served in the MT as compared to the PT cells. The
percentage of the bcl-2 positive population was how-
ever, on the contrary, slightly reduced in the MT as
compared to the PT cells (Fig. 8b).
A comparison of the p53 mutant protein in the PT
and MT cells, as detected by the PAb 240 and
Pab122 antibodies is presented in Fig. 9. While the
positive control line, p53His175, shows a consider-
able level of mutant p53, the TAU-47 PT cells ap-
pear completely negative with regard to the PAb240
and the TAU-47 MT cells are slightly positive. All
the other AKR lymphoma cells, whether deriving
from PT or MT, were negative (not shown).
As for the PAb122, negative results were obtained
with all the variants for both PT and MT cells (Fig. 9
and results which are not shown).
Fig. 10. Comparison of Fas expression in PT and MT cells of AKR lymphoma by £ow cytometry analysis.
Table 2
Comparison of mitotic and apoptotic indices and macrophage content between primary and metastatic AKR lymphoma cells
Type of cells Mitotic index (%) Apoptotic index (%) Macrophages (%)
TAU-45-PT 0.1 þ 0.1 6.1 þ 0.9 1.0 þ 0.6
TAU-45-MT 0.0 2.0 þ 0.5 0.0
TAU-44-PT 0.6 þ 0.3 10.3 þ 3.0 0.8 þ 0.6
TAU-44-MT 0.0 0.2 þ 0.0 0.0
TAU-33-PT 0.5 þ 0.4 9.2 þ 4.1 0.0
TAU-33-MT 0.0 0.0 0.0
Tumor cell suspensions were washed with PBS and the pellet was spread on slides. The cells were ¢xed with methanol and stained
with May^Grunwald^Giemsa.
The data are related to 300 cells counted at microscopic magni¢cation 400U.
BBAMCR 14625 22-5-00
S. Kay et al. / Biochimica et Biophysica Acta 1497 (2000) 37^50 45
The £ow cytometry analysis of the Fas receptor
expression (Figs. 10 and 11) shows a higher expres-
sion of the protein, as seen by both £uorescence in-
tensity (Fig. 11a) and proportion of Fas+ cells (Fig.
11b), in MT cells in comparison with PT cells. In
addition, a slight increase in Fas expression with
augmenting variant malignancy in the PT as well in
the MT cells can be seen. These results, although
surprising, can be explained as discussed later.
4. Discussion
While cell proliferative capacity and di¡erentiation
level of tumors have been for a century the estab-
lished criteria for determining disease prognosis, ten-
dency to apoptosis only recently emerged as a possi-
ble factor in the genesis and progression of cancer.
Apoptosis is known to be of importance in the
normal evolution of T lymphocytes, being responsi-
ble for the deletion of inappropriate cells in the
thymus [32]. T cell lymphomas might therefore con-
stitute a good model to study the deregulation of
PCD with relation to their formation and progres-
sion.
Our present results support and extend our pre-
vious data which suggested a role of release from
apoptosis in tumor progression of AKR lymphoma
[26]. Using various criteria (cellular morphology,
DNA £ow cytometry, DNA degradation assay) we
consistently found, in four AKR lymphoma variants,
that MT cell populations have a much lower ten-
dency to spontaneous apoptotic cell death than PT
cells (around 4% in MT cells versus ca 33% in the PT
cells). The existence of macrophages among PT cells
only, also supports the presence of apoptotic cells in
the local tumor but not in the disseminated growths.
However the presence or absence of macrophages
might have other reasons as well, such as production
of substances inhibitory to macrophages [33].
By contrast, cell proliferative ability clearly does
not seem to determine malignant behavior in the
AKR lymphoma, since MT cells exhibited, in all
variants, much lower S and G2/M phase fractions
(8% at most) than the PT cells (around 33%).
This apparently unexpected result suggests that
high proliferative ability is not essential for the meta-
static phenotype, at least not in the AKR lymphoma
system. In our T cell lymphoma system it appears
that release from apoptotic cell death rather than
cell proliferative capacity is involved in the meta-
static phenotype.
Recently a highly malignant variant of the Nb2 T
cell lymphoma line was shown to display a higher
resistance to apoptosis than a non-metastasizing
and a low-metastasizing variant [34].
An apparently paradoxical feature was observed
with regard to the PT cells of the AKR lymphoma:
they display both a high proliferative capacity and a
pronounced tendency to spontaneous apoptosis. The
existence of such a dual state is supported by the
coexistence of cell proliferation and cell death within
the same areas in various tissues [35]. An unbalanced
equilibrium between the two processes, rather than
their absolute values, may possibly be of importance
in malignancy. Interestingly, the c-myc gene induces
Fig. 11. Comparison of the Fas protein between PT and MT
cells according to £uorescence intensity peaks (a) and percent-
age of Fas positive cells (b). The average values of Fas expres-
sion were calculated as for Bcl-2 (Fig. 8).
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a state in which both cell proliferation and apoptotic
death are possible, the option depending on the
availability of growth factors [36].
At the molecular level, bcl-2 appears to play a role
in the progression of our T cell lymphoma model.
MT cells displayed a higher intensity of staining
with anti bcl-2 than the PT cells (U4.3, U3.7 and
U2.8 for the TAU-47, TAU-44 and TAU-33 var-
iants, respectively). The proportions of cells stained
are however slightly lower in the MT than in the PT
cells. It is possible that the highly expressing bcl-2
cells, even if they do not constitute the majority of
the MT cell population, they might determine the
aggressive behavior of the tumor as a whole. Xerri
et al. [37] described a higher percentage of p53+
Reed^Sternberg cells in relapsing Hodgkin’s disease
as compared to non-relapsing, but this di¡erence was
even more pronounced with regard to staining inten-
sity.
The bcl-2 molecule was usually found to block cell
death, contributing thereby to tumorigenesis [10] and
tumor progression [14]. Apoptotic cell death was not
however always found to be related to decrease in
expression of the bcl-2 gene [38]. Overexpression of
bcl-2 can both promote and impair lymphoma devel-
opment [39]. Evidence for and against an enhanced
aggressiveness of tumors overexpressing bcl-2 has
been reported [11^14].
It was suggested that since 70^90% of the malig-
nancies developing in p533/3 mice are lymphomas,
absence of p53 may be particularly devastating in the
lymphoid lineage cells [40]. Deletion of the p53 gene
has been shown to be involved in the development
[41] and increased metastatic rates [40,41] of T cell
lymphoma. We have however found only a small
involvement of mutant p53 in the malignancy of
AKR lymphoma.
Examination of the Fas antigen expression re-
vealed, surprisingly, higher levels of the receptor on
the MT than on the PT cells.
According to various data in literature, aberra-
tions in the Fas-Fas ligand apoptotic cell pathway
of tumor cells can result in: (1) release from apopto-
sis; (2) escape of the neoplastic cells from immune
surveillance; (3) counterattack of the tumor cells
against the immune system; (4) induction of apo-
ptotic cell death in the normal tissue of metastatic
target organs; (5) in certain conditions, ligation of
the Fas receptor has been shown to cause cell pro-
liferation.
Tumors may be resistant to Fas-dependent apo-
ptosis due to lack of the molecule [42,43], or part
of it [44], its downregulation [43], or defects in the
signalling pathway downstream the receptor [45]. Se-
questration of the Fas receptor in the cytoplasm,
resulting in lack of translocation of the molecule to
the cell membrane [46,47] can also be responsible for
resistance to Fas-mediated apoptosis. Resistance to
both spontaneous and immune cytotoxicity-induced
apoptosis may result from such changes.
Prominent Fas antigen expression in advanced tu-
mors was described by other authors as well in renal
cell carcinoma. Horie et al. [48] even suggested Fas
targetting as a therapeutic option for advanced
stages of this tumor which is refractory to the usual
antineoplastic treatment modalities. AIDS-related
primary CNS lymphomas (AIDS-PCNSL) show
high-density surface expression of Fas antigen [49].
These authors suggested that since the brain paren-
chyma does not express Fas receptors, local delivery
of Fas-activating molecules might be e¡ective in
treatment of AIDS-PCNSL.
In addition to the apoptosis-related genes, the ex-
pression of which we have tested, other genes might
be involved in the tumor progression of T cell lym-
phomas of mice, such as c-myc [50^52], pvt-1 [53],
pim-1 [54,55] or g¢-1 [56].
Sensitivity or resistance to apoptotic cell death in
cancer might have an importance for determining
tumor mass, genetic instability as well as vulnerabil-
ity of the tumor cells to chemotherapy and immuno-
therapy. Numerous studies report on the e¡ect of
chemotherapeutic agents via induction of apoptosis
[3,57] and drug resistance appears to be related to
escape from apoptosis [58].
We have assessed here the presence of macro-
phages in the PTs and their absence in the MT
growths. Bcl-2 was found by Albina et al. [59] to
protect P815 murine mastocytoma cells against
apoptotic cell death induced by reactive nitrogen in-
termediate-mediated macrophage cytotoxicity. These
data support a bcl-2-dependent escape of tumor cells
from innate immune surveillance. A bcl-2 protection
against apoptosis of the human T cell leukemia Jur-
kat cell line induced by CTL was also reported [60].
Deregulation of apoptosis as a mechanism of tu-
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mor progression might have practical implications
both as supplying new prognostic markers as well
as for the design of novel therapeutic modalities.
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